Thyroid C-cell adenomas occurred in rats when exposed to >15 times human exposure of 20mcg/day.L48400 Overdose is associated with GI side effects typical of GLP-1 receptor agonists.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the USL763 and Lyxumia in the EU.L764 Adlyxin recieved FDA approval July 28, 2016.L763
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Pegvisomant | The risk or severity of hypoglycemia can be increased when Pegvisomant is combined with Lixisenatide. |
| Lipoic acid | The risk or severity of hypoglycemia can be increased when Lipoic acid is combined with Lixisenatide. |
| Moxifloxacin | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Moxifloxacin. |
| Grepafloxacin | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Grepafloxacin. |
| Enoxacin | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Enoxacin. |
| Pefloxacin | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Pefloxacin. |
| Ciprofloxacin | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Ciprofloxacin. |
| Trovafloxacin | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Trovafloxacin. |
| Nalidixic acid | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Nalidixic acid. |
| Rosoxacin | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Rosoxacin. |
| Cinoxacin | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Cinoxacin. |
| Lomefloxacin | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Lomefloxacin. |
| Gatifloxacin | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Gatifloxacin. |
| Norfloxacin | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Norfloxacin. |
| Levofloxacin | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Levofloxacin. |
| Gemifloxacin | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Gemifloxacin. |
| Ofloxacin | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Ofloxacin. |
| Sparfloxacin | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Sparfloxacin. |
| Temafloxacin | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Temafloxacin. |
| Fleroxacin | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Fleroxacin. |
| Technetium Tc-99m ciprofloxacin | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Technetium Tc-99m ciprofloxacin. |
| Garenoxacin | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Garenoxacin. |
| Nemonoxacin | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Nemonoxacin. |
| Flumequine | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Flumequine. |
| Enrofloxacin | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Enrofloxacin. |
| Orbifloxacin | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Orbifloxacin. |
| Sarafloxacin | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Sarafloxacin. |
| Difloxacin | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Difloxacin. |
| Pazufloxacin | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Pazufloxacin. |
| Prulifloxacin | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Prulifloxacin. |
| Delafloxacin | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Delafloxacin. |
| Sitafloxacin | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Sitafloxacin. |
| Oxolinic acid | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Oxolinic acid. |
| Rufloxacin | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Rufloxacin. |
| Pipemidic acid | The therapeutic efficacy of Lixisenatide can be increased when used in combination with Pipemidic acid. |
| Methyclothiazide | The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Methyclothiazide. |
| Chlorthalidone | The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Chlorthalidone. |
| Bendroflumethiazide | The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Bendroflumethiazide. |
| Metolazone | The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Metolazone. |
| Benzthiazide | The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Benzthiazide. |
| Hydroflumethiazide | The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Hydroflumethiazide. |
| Indapamide | The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Indapamide. |
| Chlorothiazide | The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Chlorothiazide. |
| Hydrochlorothiazide | The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Hydrochlorothiazide. |
| Trichlormethiazide | The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Trichlormethiazide. |
| Polythiazide | The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Polythiazide. |
| Quinethazone | The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Quinethazone. |
| Cyclopenthiazide | The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Cyclopenthiazide. |
| Epitizide | The therapeutic efficacy of Lixisenatide can be decreased when used in combination with Epitizide. |
| Protriptyline | Protriptyline may decrease the hypoglycemic activities of Lixisenatide. |
| Nortriptyline | Nortriptyline may decrease the hypoglycemic activities of Lixisenatide. |
| Amoxapine | Amoxapine may decrease the hypoglycemic activities of Lixisenatide. |
| Trimipramine | Trimipramine may decrease the hypoglycemic activities of Lixisenatide. |
| Amineptine | Amineptine may decrease the hypoglycemic activities of Lixisenatide. |
| Butriptyline | Butriptyline may decrease the hypoglycemic activities of Lixisenatide. |
| Dosulepin | Dosulepin may decrease the hypoglycemic activities of Lixisenatide. |
| Tianeptine | Tianeptine may decrease the hypoglycemic activities of Lixisenatide. |
| Oxaprotiline | Oxaprotiline may decrease the hypoglycemic activities of Lixisenatide. |
| Opipramol | Opipramol may decrease the hypoglycemic activities of Lixisenatide. |
| Amitriptylinoxide | Amitriptylinoxide may decrease the hypoglycemic activities of Lixisenatide. |
| Dibenzepin | Dibenzepin may decrease the hypoglycemic activities of Lixisenatide. |
| Quinupramine | Quinupramine may decrease the hypoglycemic activities of Lixisenatide. |
| Melitracen | Melitracen may decrease the hypoglycemic activities of Lixisenatide. |
| Lofepramine | Lofepramine may decrease the hypoglycemic activities of Lixisenatide. |
| Iprindole | Iprindole may decrease the hypoglycemic activities of Lixisenatide. |
| Imipramine oxide | Imipramine oxide may decrease the hypoglycemic activities of Lixisenatide. |
| Amitriptyline | Amitriptyline may decrease the hypoglycemic activities of Lixisenatide. |
| Imipramine | Imipramine may decrease the hypoglycemic activities of Lixisenatide. |
| Doxepin | Doxepin may decrease the hypoglycemic activities of Lixisenatide. |
| Desipramine | Desipramine may decrease the hypoglycemic activities of Lixisenatide. |
| Clomipramine | Clomipramine may decrease the hypoglycemic activities of Lixisenatide. |
| Dimetacrine | Dimetacrine may decrease the hypoglycemic activities of Lixisenatide. |
| Dicoumarol | Lixisenatide can cause a decrease in the absorption of Dicoumarol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Phenindione | Lixisenatide can cause a decrease in the absorption of Phenindione resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Warfarin | Lixisenatide can cause a decrease in the absorption of Warfarin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Phenprocoumon | Lixisenatide can cause a decrease in the absorption of Phenprocoumon resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Acenocoumarol | Lixisenatide can cause a decrease in the absorption of Acenocoumarol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| 4-hydroxycoumarin | Lixisenatide can cause a decrease in the absorption of 4-hydroxycoumarin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Coumarin | Lixisenatide can cause a decrease in the absorption of Coumarin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| (R)-warfarin | Lixisenatide can cause a decrease in the absorption of (R)-warfarin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ethyl biscoumacetate | Lixisenatide can cause a decrease in the absorption of Ethyl biscoumacetate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fluindione | Lixisenatide can cause a decrease in the absorption of Fluindione resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Clorindione | Lixisenatide can cause a decrease in the absorption of Clorindione resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Diphenadione | Lixisenatide can cause a decrease in the absorption of Diphenadione resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tioclomarol | Lixisenatide can cause a decrease in the absorption of Tioclomarol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| (S)-Warfarin | Lixisenatide can cause a decrease in the absorption of (S)-Warfarin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Glimepiride | The risk or severity of hypoglycemia can be increased when Lixisenatide is combined with Glimepiride. |
| Acetohexamide | The risk or severity of hypoglycemia can be increased when Lixisenatide is combined with Acetohexamide. |
| Chlorpropamide | The risk or severity of hypoglycemia can be increased when Lixisenatide is combined with Chlorpropamide. |
| Tolazamide | The risk or severity of hypoglycemia can be increased when Lixisenatide is combined with Tolazamide. |
| Glyburide | The risk or severity of hypoglycemia can be increased when Lixisenatide is combined with Glyburide. |
| Glipizide | The risk or severity of hypoglycemia can be increased when Lixisenatide is combined with Glipizide. |
| Gliclazide | The risk or severity of hypoglycemia can be increased when Lixisenatide is combined with Gliclazide. |
| Tolbutamide | The risk or severity of hypoglycemia can be increased when Lixisenatide is combined with Tolbutamide. |
| Gliquidone | The risk or severity of hypoglycemia can be increased when Lixisenatide is combined with Gliquidone. |
| Glisoxepide | The risk or severity of hypoglycemia can be increased when Lixisenatide is combined with Glisoxepide. |
| Glibornuride | The risk or severity of hypoglycemia can be increased when Lixisenatide is combined with Glibornuride. |
| Carbutamide | The risk or severity of hypoglycemia can be increased when Lixisenatide is combined with Carbutamide. |
| Metahexamide | The risk or severity of hypoglycemia can be increased when Lixisenatide is combined with Metahexamide. |
| Dapagliflozin | Dapagliflozin may increase the hypoglycemic activities of Lixisenatide. |